- Home
- IDAI vs TOVX Comparison
IDAI vs TOVX Comparison
Compare IDAI & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IDAI
- TOVX
- Stock Information
- Founded
- IDAI 2016
- TOVX 2001
- Country
- IDAI United States
- TOVX United States
- Employees
- IDAI N/A
- TOVX N/A
- Industry
- IDAI Computer Software: Prepackaged Software
- TOVX Biotechnology: Pharmaceutical Preparations
- Sector
- IDAI Technology
- TOVX Health Care
- Exchange
- IDAI Nasdaq
- TOVX Nasdaq
- Market Cap
- IDAI 5.5M
- TOVX 4.7M
- IPO Year
- IDAI N/A
- TOVX 2006
- Fundamental
- Price
- IDAI $1.88
- TOVX $1.18
- Analyst Decision
- IDAI
- TOVX Strong Buy
- Analyst Count
- IDAI 0
- TOVX 1
- Target Price
- IDAI N/A
- TOVX $6.00
- AVG Volume (30 Days)
- IDAI 73.9K
- TOVX 23.1K
- Earning Date
- IDAI 05-13-2025
- TOVX 05-06-2025
- Dividend Yield
- IDAI N/A
- TOVX N/A
- EPS Growth
- IDAI N/A
- TOVX N/A
- EPS
- IDAI N/A
- TOVX N/A
- Revenue
- IDAI $3,082,348.00
- TOVX N/A
- Revenue This Year
- IDAI $66.11
- TOVX N/A
- Revenue Next Year
- IDAI N/A
- TOVX N/A
- P/E Ratio
- IDAI N/A
- TOVX N/A
- Revenue Growth
- IDAI N/A
- TOVX N/A
- 52 Week Low
- IDAI $0.15
- TOVX $1.03
- 52 Week High
- IDAI $8.96
- TOVX $12.25
- Technical
- Relative Strength Index (RSI)
- IDAI 38.52
- TOVX 44.05
- Support Level
- IDAI $1.73
- TOVX $1.08
- Resistance Level
- IDAI $2.16
- TOVX $1.25
- Average True Range (ATR)
- IDAI 0.26
- TOVX 0.08
- MACD
- IDAI 0.01
- TOVX 0.00
- Stochastic Oscillator
- IDAI 17.31
- TOVX 57.89
About IDAI T Stamp Inc.
T Stamp Inc develops and markets identity authentication software solutions for enterprise partners and peer-to-peer markets. The company is engaged in developing proprietary artificial intelligence-powered solutions; researching and leveraging biometric science, cryptography, and data mining to deliver insightful identity & trust predictions while identifying and defending against fraudulent identity attacks, protecting sensitive user information, and extending the reach of digital services through accessibility.
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.